ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1945

Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients with Giant Cell Arteritis
Abstract Number: 0644

Characterizations of Cytokine Storm Associated with COVID19
Abstract Number: 0072

Characterizing Heterogeneity of Synovial Macrophages in Rheumatoid Arthritis Patients
Abstract Number: 1301

Characterizing How SLE Patients Access Health Information Pre and During COVID-19
Abstract Number: 2038

Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis
Abstract Number: 1223

Characterizing Rheumatoid Arthritis Patients by Their Biologic DMARD Prescription History
Abstract Number: 0398

Chest CT Ordering Practices at Expert Scleroderma Centers in the United States
Abstract Number: 0695

Chronic Inflammatory Back Pain Occurring Later in Life: A Neglected Concept
Abstract Number: 0182

Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists
Abstract Number: 0083

Chronic Nonbacterial Osteomyelitis Is Associated with HLA-B*27
Abstract Number: 0963

Chronic Obstructive Pulmonary Disease Associated with Prolonged Opiate Use, Increased Short-Term Complications and the Need for Revision Surgery Following Total Knee Arthroplasty
Abstract Number: 0444

Chronological Order of Decrease of Synovitis, Osteitis and Tenosynovitis in Early Arthritis Patients Receiving First DMARD-treatment
Abstract Number: 1558

Cinematic Rendering Enables Depiction of Bone Anabolic Effects in Patients Treated with Baricitinib
Abstract Number: 2004

Circulating Biomolecules as Potential Biomarkers of Early and Establishedresponse to TNFi Therapy in Rheumatoid Arthritis Patients
Abstract Number: 0744

Circulating Fibroblast Growth Factor-21 Levels in Rheumatoid Arthritis: Associations with Disease Characteristics, Body Composition, and Physical Functioning

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].